Flt-4 Antibody (G-3): sc-365748

Flt-4 Antibody (G-3) is a mouse monoclonal IgG3 antibody that detects Flt-4 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Flt-4, also known as vascular endothelial growth factor receptor 3 (VEGFR-3), plays a crucial role in lymphangiogenesis and the development of the lymphatic system, which is essential for maintaining fluid homeostasis and immune responses. VEGFR-3 is primarily located on the surface of endothelial cells, particularly in lymphatic vessels, where VEGFR-3 mediates the effects of vascular endothelial growth factors, specifically VEGF-C and VEGF-D. This interaction is vital for the regulation of lymphatic endothelial cell proliferation and migration, thereby influencing the formation of new lymphatic vessels. Dysregulation of VEGFR-3 signaling has been implicated in various pathological conditions, including cancer metastasis and lymphedema, making VEGFR-3 a significant target for therapeutic interventions. anti-Flt-4 antibody (G-3) provides a reliable tool for researchers studying these critical processes and the underlying mechanisms of diseases associated with lymphatic dysfunction.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Flt-4 Antibody (G-3) References:

1. Expression and significance of VEGF-C and FLT-4 in gastric cancer.  |  Liu, XE., et al. 2004. World J Gastroenterol. 10: 352-5. PMID: 14760756
2. Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis.  |  Stearns, ME., et al. 2004. Lab Invest. 84: 785-95. PMID: 15107801
3. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells.  |  Su, JL., et al. 2006. Cancer Cell. 9: 209-23. PMID: 16530705
4. Apoptosis of human macrophages by Flt-4 signaling: implications for atherosclerotic plaque pathology.  |  Schmeisser, A., et al. 2006. Cardiovasc Res. 71: 774-84. PMID: 16887107
5. The role of VEGF-C/D and Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma.  |  Yu, H., et al. 2009. J Exp Clin Cancer Res. 28: 98. PMID: 19589137
6. The role of the VEGF-C/-D/flt-4 autocrine loop in the pathogenesis of salivary neoplasms.  |  Tampouris, AI., et al. 2012. Pathol Res Pract. 208: 151-6. PMID: 22326635
7. VEGF-C/Flt-4 axis in tumor cells contributes to the progression of oral squamous cell carcinoma via upregulating VEGF-C itself and contactin-1 in an autocrine manner.  |  Shigetomi, S., et al. 2018. Am J Cancer Res. 8: 2046-2063. PMID: 30416855
8. Therapeutic potential of FLT4-targeting peptide in acute myeloid leukemia.  |  Lee, JY., et al. 2023. Cancer Immunol Immunother.. PMID: 36763100
9. Coexpression of flt-1, flt-4 and KDR in freshly isolated and cultured human endothelial cells.  |  Hewett, PW. and Murray, JC. 1996. Biochem Biophys Res Commun. 221: 697-702. PMID: 8630024
10. Characterization of murine Flt4 ligand/VEGF-C.  |  Fitz, LJ., et al. 1997. Oncogene. 15: 613-8. PMID: 9247316

The preferred Flt-4 antibody is Flt-4 Antibody (D-6): sc-28297.